Combines Extensive Contact Lens & Pharma Experience
Press Releases
Â
FOR IMMEDIATE RELEASE
Â
Freya Ophthalmics Secures Major Investment Milestone, Accelerates Development of Groundbreaking Drug-Eluting Contact Lens Platform
[Jacksonville, Florida] — [October 29, 2025] — Freya Ophthalmics Inc., a pioneering biotech company developing a first-in-class drug-eluting contact lens platform for delivery of ocular therapy, today announced significant progress in its $14.25 million Series A funding round. The company has secured a substantial portion of its target raise, fully funding the costs associated with its Phase 2 clinical trials in Australia. To finalize the Series A raise, Freya is seeking an additional $750,000 investment.Â
Freya Ophthalmics is transforming ocular drug delivery through its proprietary platform—essentially a clear, vision-preserving contact lens that delivers sustained, targeted treatment for a range of ocular diseases. The innovation offers a compelling alternative to eye drops and injections by enhancing compliance, safety, and clinical outcomes.
The company is led by an accomplished team including Craig Walker as Chief Executive Officer, Dr. Anuj Chauhan as Chief Technology Officer, Cynthia Matossian, MD, as Chief Medical Officer, and Tom Mitro as Commercial Expert Director. Together with a network of global partners, the team is driving toward their clinical programs and is preparing for commercial scalability.
“We’re excited about the momentum we’ve built and the strong investor interest we’ve received,” said Craig Walker, CEO of Freya Ophthalmics. “Our technology offers a unique value proposition for both patients and providers, and we believe Freya is well-positioned to deliver significant clinical impact and financial reward.”
Freya is actively engaging with investors who have a focus on early-stage healthcare innovation, particularly in ophthalmology and drug delivery.
For more information, to schedule a meeting, or to request Freya’s non-confidential investor deck, please contact Craig WalkerÂ
About Freya Ophthalmics
Freya Ophthalmics Inc. is a privately held biotech company redefining ocular care through its innovative drug-eluting contact lens platform. Headquartered in Jacksonville, Florida, Freya is focused on delivering non-invasive, sustained-release therapies for patients suffering from a range of ocular conditions.
Craig Walker
Chief Executive Officer
Freya Ophthalmics Inc
Creating a New and Better Era in Ocular Drug Delivery
c: Â 904-629-2455
Â